Member Info for Bridges

sar is not index linked to ftse or any other index? Think MM raiding stops. If they wanted to create liquidity then they could try the higher momentum with all the good news. What is it with these guys they killing the momentum. Let’s see what they are up to at the end of the day. Next week LSX plus Frankfurt exchange on line.

James you can’t prove there isn’t either lol

Just to clarify the MM have strangled the liquidity

num4 dealers have different strategies and may have slowed it down. However imho they have strangled the liquidity and momentum as value of sp should be around 8p given all the good news we have had but they have strangled it.

Hey Lazarus 2 I think that there are undercurrents that we are not aware of but it is frustrating sitting in the stands wanting to get on the pitch and score the winning goal. Only consolation IMHO is that we have some vomit bucket days to come.

There was a pre presentation recorded available that was commented on all day yesterday and I think some got confused thinking it was the 2:30pm event. The event was a closed shop.

Hey J4F/Casper Considering the hand held attendance to the Edison Open House - Global Healthcare and next week LSX I would be surprised if we dont get investment from either, in particular yesterdays event ; very interesting timing. Venture capital money plus VC expertise to drive large scale licencing deals or more probable a TO deal. This scenario looks probable and imho a win win for SAR. On the Edison Open House event it is worth noting that Sareum has been hand held /picked to attend (last min) in amongst a small amount of hand-picked companies most high profile, such as Oxford BioMedica and some yet to gain mainstream attention such as SAR. IMHO there will be no need for a placing due to the above and most likely further grant from Boris GLA ... a very interesting turn of events.

Sar are selling their IP and I guess that attending an event swarmed with deep pocket venture capitalists is insider info. It is another signal to the market that a deal is near and it won’t involve the MM forward sold position (thinking there was going to be a placing).

Don’t let them expire otherwise they will be borrowed ; )

They usually expire after 90 days on HL you need to replace the sell limit order

The last min decision to join Edison indicates that they were hand held into it, someone has an agenda.

Hey Lazarus will not be a 5 min job if they get a deal. Maybe can reach an MOU fairly quickly but any details of a deal will need to be agreed, contract formulation then through both legal sides.

It was a closed drop-in I believe ... venture capitalists and the like. There will be no link to share ;)

Hey Lazarus i tend to agree that we will more than likely not get an RNS immediately but I would be surprised if we dont get investment from either this event or LSX; very interesting timing. If we dont get direct investment then maybe SAR will be attractive to be part of in terms of adding to a portfolio. I worked for a large venture capitalist, probably the largest at the time, in the 90s and SAR is exactly the type of company that would get picked. Just imagine venture capital money plus their expertise to drive large scale licencing deals or more probably TO. I know which one i would prefer and if my hunch is correct then we are ion for a ride sooner than later.

Well articulated Jus4fun. May i also add ....
Furthermore, disease model studies have reported that specifically inhibiting TYK2 activity restores the body's ability to protect against bacterial pneumonia following influenza infection2, suggesting that a TYK2 inhibitor, such as SDC-1801, may have the same effect in Covid-19 patients. Serious bacterial infections have been reported in up to 50% of critically ill Covid-19 patients.

closed shop unless you are venture capitalist. May get an RNS this week with any market sensitive info.

Big Pharma will be paying attention to 1801, what with Edison Open House and LSX next week plus huge exposure globally on therapeutics IMHO i expect an approach possibly a bid Q1. The world is waking up to early therapeutics will drive down cost and most importantly save lives. I would love to be negotiating this deal, probably shares this with a few but a tad frustrating sitting outside of this.

Num4 I agree good synopsis, there are big pocket names on the Edison list that would be open for investment. Big Pharma will become aware of this intention and question whether they would want to get in first otherwise being held to ransom later by savvy venture capitalist. Win win scenario as you put it.

https://www.lsegissuerservices.com/spark/SareumHoldings/events/66b15002-ca20-4983-a9b2-c1371b60321b

The interview from the core studio clearly sets out the BOD commercialisation strategy.
Early Clinical for autoimmune, covid and cancer therapy Ph 1 / 2 MAX
Preclinical funded 1801 Looking for early licence deal or raise funds to go into clinic.
2021 - Closing comments .... Good data set to strike licence deal. For me this is clearly the BODs intention and not to raise funds.

I think my hunch is correct that they have progressed c. 60% of the way through the investigation into the therapeutic potential of SDC-1801 and the study into how this small molecule as the TYK2/JAK1 kinase inhibitor. This proves that they are substantially ready for CTA approval the following human trails possibly in March.
I also think that early treatment of COVID is key to lowering death rates, the first sign of falling oxygen levels should be the start of therapeutic treatment . Well done BOD keep up the good work to save lives!